XML 32 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity Method Accounting for Common Stock of OncoCyte, at fair value (Tables)
 3 Months Ended
Mar. 31, 2017
OncoCyte [Member]  
Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract]  
Unaudited results of operations and condensed balance sheet information
The unaudited condensed results of operations for the three months ended March 31, 2017 and 2016, the unaudited condensed balance sheet information of OncoCyte at March 31, 2017 and the audited balance sheet information of OncoCyte at December 31, 2016 are summarized below (in thousands):

  
January 1, 2017 to
February 16, 2017
(unaudited)
  
February 17, 2017
to March 31, 2017
(unaudited)
  
Three Months Ended
March 31, 2016
(unaudited)
 
Condensed Statements of Operations (1):
         
Research and development expense
 
$
798
  
$
1,049
  
$
1,835
 
General and administrative expense
  
590
   
2,093
   
1,751
 
Loss from operations
  
(1,388
)
  
(3,142
)
  
(3,586
)
Net loss
 
$
(1,932
)
 
$
(3,311
)
 
$
(3,582
)

  
March 31, 2017
(unaudited)
  
December 31, 2016
 
Condensed Balance Sheet information (2):
      
Current assets
 
$
13,452
  
$
10,459
 
Noncurrent assets
  
1,722
   
1,751
 
  
$
15,174
  
$
12,210
 
         
Current liabilities
 
$
4,549
  
$
1,421
 
Noncurrent liabilities
  
1,852
   
310
 
Stockholders’ equity
  
8,773
   
10,479
 
  
$
15,174
  
$
12,210